Targeting the reward circuitry: low-dose methylphenidate for motivational anhedonia in pediatric depression

Introduction

Anhedonia, a common finding in many psychiatric disorders, can be categorized into anticipatory/motivational or consumatory types based on the reward circuit [1, 2]. Motivational anhedonia, roughly defined by a reduced drive to pursue pleasurable activities, often remains refractory to standard antidepressant treatments like selective serotonin reuptake inhibitors (SSRI) [3, 4]. This may be attributed to its association with the mesocorticolimbic pathways, primarily mediated by dopamine and norepinephrine [1, 4].

This case report details the use of methylphenidate in a prepubertal boy presenting with motivational anhedonia that was refractory to SSRI monotherapy and augmentation with atypical antipsychotics. Verbal consent was obtained from the patient’s parent.

Case Presentation

An 11-year-old boy, weighing 71 kg, was admitted to our child and adolescent psychiatry outpatient clinic with a several-month history of social withdrawal, low energy, and school non-attendance. His clinical history includes school refusal at the age of seven, briefly treated with fluoxetine. He and his mother were evicted by his substance-abusing father three years ago.

In our first examination, the patient presented with restricted affect and showed indifference to his surroundings. Clinical and psychometric evaluations (Revised Children’s Anxiety and Depression Scale, Children’s Depression Inventory, Conners Rating Scales, Child Behavior Checklist, Beier Sentence Completion Test, and Swanson, Nolan, and Pelham IV (SNAP-IV) Rating Scale) indicated a latent desire to return to his academic environment. The presentation did not meet formal DSM-5 diagnostic criteria for PTSD or ADHD. He was diagnosed with an unspecified depressive disorder.

Prior to admission, the patient was treated with fluoxetine, titrated to 40 mg/day over three months. While mood symptoms improved, no significant progress was observed in school attendance.

We augmented the treatment with aripiprazole (5 mg/day) and clonazepam (0.5 mg BID), but the patient showed no clinical improvement and behavioral activation interventions failed. Recognizing the presentation as a failure of motivation, we discontinued the antipsychotic and benzodiazepine and initiated low-dose methylphenidate (5 mg/day) as an augmentation to the fluoxetine. Within three weeks, the patient showed a dramatic increase in social engagement and energy. Treatment was well-tolerated without significant adverse effects. He later successfully engaged with the graded exposure plan and returned to full-time schooling.

Discussion

Concerns exist regarding the use of psychostimulants in major depressive disorder, and clinical trials have failed [5]. However, there is also evidence that psychostimulants may be useful for motivational anhedonia and could be used as a facilitating treatment [1, 3]. Recent studies on anhedonia indicate a correlation between motivational/anticipatory components and striatal dopamine hypoactivation, which psychostimulants may target [4].

In this case, for our psychosocial interventions to be effective, we first needed to biologically support the patient’s motivation. While many agents reported to be beneficial in SSRI-resistant motivational anhedonia lack regulatory approval for children, we utilized low-dose methylphenidate—a well-established agent in this population with a similar mechanism to bupropion—to provide the necessary dopaminergic-noradrenergic stimulation.

Conclusions

Regulating negative affect alone is insufficient for full recovery in depressive patients. There is a need for clinical pharmacological studies in children and adolescents regarding motivational anhedonia in a transdiagnostic aspect rather than focusing on categorical diagnoses.

References

1. Al-Soleiti, M., Vande Voort, J.L., Singh, B., 2025. Anhedonia as a core symptom of depression and a construct for Biological Research. Focus 23, 163–172. doi:10.1176/appi.focus.20240050.
2. Ely, B.A., Nguyen, T.N., Tobe, R.H., Walker, A.M., Gabbay, V., 2021. Multimodal investigations of reward circuitry and anhedonia in adolescent depression. Frontiers in Psychiatry 12. doi:10.3389/fpsyt.2021.678709.
3. Serretti, A., 2025. Anhedonia: Current and future treatments. Psychiatry and Clinical Neurosciences Reports 4. doi:10.1002/pcn5.70088.
4. Borsini, A., Wallis, A.S., Zunszain, P., Pariante, C.M., Kempton, M.J., 2020. Characterizing anhedonia: A systematic review of neuroimaging across the subtypes of reward processing deficits in depression. Cognitive, Affective, & Behavioral Neuroscience 20, 816–841. doi:10.3758/s13415-020-00804-6.
5. Malhi, G.S., Byrow, Y., Bassett, D., Boyce, P., Hopwood, M., Lyndon, W., Mulder, R., Porter, R., Singh, A., Murray, G., 2016. Stimulants for depression: On the UP and up? Australian & New Zealand Journal of Psychiatry 50, 203–207. doi:10.1177/0004867416634208